Table 3.
Metabolomics according to therapy against Anti-Her2
| Metabolite | pVal | FDR | Fold Change | log2FC |
|---|---|---|---|---|
| Met | 0.000225 | *0.033471 | 1.14504 | 0.195398 |
| Met-SO | 0.00418 | 0.311396 | 1.183643 | 0.243233 |
| C5 | 0.029313 | 0.796629 | −1.71614 | −0.77917 |
| GDCA | 0.053344 | 0.796629 | 1.613991 | 0.690632 |
| SM C18:0 | 0.057353 | 0.796629 | −1.10374 | −0.1424 |
| Ser | 0.061827 | 0.796629 | 1.102561 | 0.140859 |
| PC aa C42:0 | 0.0629 | 0.796629 | 1.128321 | 0.174178 |
| Tyr | 0.068192 | 0.796629 | 1.069945 | 0.097537 |
| His | 0.068498 | 0.796629 | 1.047076 | 0.066366 |
| Gln | 0.075358 | 0.796629 | 1.056773 | 0.079666 |
*FDR ≤ 0.05 (regarded as significantly different)
pVal p value; FDR false discovery rate; Log2FC log2 fold change; Met methionine; Met-SO methionine sulfoxide; C5 valerylcarnitine; GDCA glycodeoxycholic acid; SM C18.0 sphingolipid octadecanoylcarnitine, Ser serine; PC aa C42.0 glycerolipid dotetracontaylcarnitine Tyr tyrosine; His histidine; Gln glutamine